ALX Oncology Holdings ALXO 深 沪
等待开盘 02-04 09:30:00 美东时间
1.805
+0.125
+7.44%
华盛通- 最 高1.879
- 今 开1.70
- 成交量 16.49万股
- 最 低 1.66
- 昨 收 1.68
- 总市值 9646.64万
- 52周最高 2.27
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.404
- 委 比 52.94%
- 总股本 5344.40万
- 历史最高 117.45
- 量 比 0.92
- 振 幅 13.04%
- 历史最低 0.404
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Friday after President Donald Trump nominated for
01-31 02:38
ALX Oncology announces major underwritten public equity offering
The latest announcement is out from ALX Oncology Holdings ( ($ALXO) ). On Janua...
01-30 21:58
ALX Oncology Highlights Biomarker Data and Cash Position
ALX Oncology Holdings ( ($ALXO) ) just unveiled an update. On January 30, 2026,...
01-30 21:52
ALX Oncology Prices ~$150M Offering Of Common Share, Pre-Funded Warrants
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the pricing
01-30 21:44
ALX Oncology Data From Phase 1b/2 Clinical Study Of CD47-Inhibitor Evorpacept In Combination With Jazz Pharmaceuticals' ZIIHERA Demonstrates CD47 Expression Is Predictive Of Evorpacept Activity
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced new data from a
01-30 21:18
ALX Oncology Reports CD47 Biomarker Predicts Response to Evorpacept in Advanced HER2-Positive Breast Cancer
ALX Oncology Reports CD47 Biomarker Predicts Response to Evorpacept in Advanced HER2-Positive Breast Cancer ALX Oncology Holdings Inc. has announced new data from a Phase 1b/2 clinical trial evaluating its investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatama
01-30 21:15
ALX Oncology Announces Pricing of Underwritten Offering
ALX Oncology announced the pricing of an underwritten offering, selling 76.98 million common shares and 18.57 million pre-funded warrants, at $1.57 and $1.569 respectively, to raise approximately $150 million. The proceeds will fund clinical development of evorpacept and ALX2004 programs, as well as general corporate purposes. The offering is led by RA Capital Management and TCGX, with participation from other investors, and is expected to close ...
01-30 13:30
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
ALX Oncology announced new data from a Phase 1b/2 trial showing that CD47 expression predicts response to evorpacept in HER2-positive metastatic breast cancer patients, consistent with findings from the ASPEN-06 gastric cancer trial. Full biomarker analysis will be presented at an upcoming conference.
01-30 13:15
ALX Oncology Expands Inducement Equity Plan With Additional 1.3 Million Shares
ALX Oncology Expands Inducement Equity Plan With Additional 1.3 Million Shares ALX Oncology Holdings Inc. has amended its 2025 Inducement Equity Incentive Plan, increasing the total number of shares reserved for issuance under the plan by 1,300,000, bringing the aggregate total to 2,800,000 shares.
01-22 05:44
ALX Oncology Doses First Patient In Phase 2 ASPEN-09-Breast Trial Evaluating Its Investigational CD47-Inhibitor Evorpacept.
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated
01-08 21:32
